Gensia Pharmaceuticals Inc. stock (NASDAQ:GNSA) jumped$4.38 to close at $43.50 on Tuesday after the San Diegocompany said its Gensia Laboratories Ltd. subsidiary hasreceived abbreviated new drug application approvals from theFood and Drug Administration for two injectable generic drugs,methyldopate and metoclopramide. Methyldopate is acardiovascular drug used for the hospital-based treatment ofacute hypertension. Metoclopramide is used in the hospital forthe prevention of nausea and vomiting following chemotherapyor surgery.

(c) 1997 American Health Consultants. All rights reserved.